Breaking news on life science and diagnostics business, policy, and funding
The new recommendation is a positive for Qiagen and Oxford Immunotec, both of which market interferon gamma-release assays.
The companies will work together to develop a series of cancer screening tests that employ Preora's cytology platform and its sample-preparation technologies.
Genoptix terminated the merger agreement after an insufficient number of Rosetta shareholders voted in favor of the deal.
The company said 571,000 people were screened for colon cancer with its noninvasive Cologuard test in 2017.
Excluding the sale of the company's colorectal cancer patents to Exact Sciences, its 2017 revenues rose 13 percent.